More Stories

Informist, Monday, Apr. 13, 2026

 

--Mankind Pharma COO: Eyeing INR 30 bln revenue from semaglutide in 3-5 yrs 
--Mankind Pharma COO: Launched semaglutide injection last week 
--Mankind Pharma COO: Launched semaglutide at INR 3,000-INR 5,000 price

 

By Gunjan Rajput and Krity Ambey

 

NEW DELHI – India's leading pharmaceutical firm Mankind Pharma Ltd. launched its semaglutide injections "last week", with pricing in the range of INR 3,000-INR 5,000, Chief Operating Officer Arjun Juneja said Monday. The company is eyeing revenue of up to INR 30 billion from the drug in the next three-five years, Juneja added. 

 

As of now, the company does not have an estimate for sales in the current financial year, Juneja told Informist on the sidelines of the India Pharma 2026, organised by the Federation of Indian Chambers of Commerce and Industry. "It takes time for demand to build up, and it is still early days to give an estimate," Juneja said.  

 

In an analyst call in February, Mankind Pharma had said it was planning to launch the drug, used for weight loss, by March. The company has not yet spoken about this launch.

 

For the December quarter, Mankind Pharma had reported 12% growth in net sales at INR 35.67 billion. Its consolidated net profit had also increased 8% on year to INR 4.09 billion in Oct-Dec. At 1513 IST, shares of Mankind Pharma were trading 0.1% lower at INR 2,076.20. 

 

Following the expiry of Novo Nordisk's patent for semaglutide on Mar. 20, over 10 Indian pharmaceutical companies have launched glucagon-like peptide-1 drugs, including semaglutide, with monthly treatment costs typically ranging from INR 1,800 to INR 5,200, significantly lower than treatment with innovator Novo Nordisk's product, which costs over INR 10,000 a month. Novo Nordisk has also reduced the prices of its semaglutide brands Ozempic by up to 36% and Wegovy by up to 48%, with monthly treatment now costing about INR 5,660–INR 9,100, depending on dosage.

The semaglutide market in India is expected to grow to over INR 120 billion by 2031, according to Nomura Financial Advisory and Securities India Pvt. Ltd. Prices of the drug are likely to decline further as volumes gradually increase over time, Nomura said in a recent research report.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Avishek Dutta

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.